- Home
- NSTS vs NRXS Comparison
NSTS vs NRXS Comparison
Compare NSTS & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NSTS | NRXS |
|---|---|---|
| Founded | 1921 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.6M | 78.9M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | NSTS | NRXS |
|---|---|---|
| Price | $14.02 | $6.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 8.2K | ★ 80.5K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | $252,000.00 | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $10.73 | $2.21 |
| 52 Week High | $14.05 | $9.33 |
Technical Indicators
Market Signals| Indicator | NSTS | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 73.54 | 42.39 |
| Support Level | $13.70 | $6.04 |
| Resistance Level | $14.04 | $7.37 |
| Average True Range (ATR) | 0.05 | 0.24 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 80.95 | 43.89 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).